Seeking Alpha

Big pharma investing in regenerative medicine

  • Large cap pharma and biotech firms have regenerative therapy R&D programs underway according to a recent survey.
  • 69% of respondents are focused on developing cellular-based therapies.
  • Wound healing and burns have the greatest near-term potential.
  • Long term areas of interest are cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease.
  • (AGN) (AMGN) (BAX) (BIIB) (CELG) (LLY) (GSK) (JNJ) (NVS) (NVO) (PFE) (RHHBY) (SNY) (MRK) (SHPG)
Comments (2)
  • rongood
    , contributor
    Comments (10) | Send Message
     
    And the news is?
    26 Mar, 09:09 AM Reply Like
  • Joe McCann
    , contributor
    Comments (68) | Send Message
     
    Should probably mention the MDWD IPO in this since they are a burn play.

     

    I bought the IPO, but slightly worried if this is true now that MDWD was willing to price at the low end of their range in a M&A hungry landscape.

     

    Remember Shire bought Advanced BioHealing the night before they IPO'ed, in 2011, so companies are debating M&A vs. IPO right up until the last minute.

     

    Maybe their product isn't regenerative enough, and really more just burn wound medicine?
    26 Mar, 12:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|